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Development of a decision analytic model
to support decision making and risk
communication about thrombolytic
treatment
Peter McMeekin1,4*, Darren Flynn1, Gary A. Ford2, Helen Rodgers2, Jo Gray4 and Richard G. Thompson1
Abstract
Background: Individualised prediction of outcomes can support clinical and shared decision making. This paper
describes the building of such a model to predict outcomes with and without intravenous thrombolysis treatment
following ischaemic stroke.
Methods: A decision analytic model (DAM) was constructed to establish the likely balance of benefits and risks of
treating acute ischaemic stroke with thrombolysis. Probability of independence, (modified Rankin score mRS ≤
2), dependence (mRS 3 to 5) and death at three months post-stroke was based on a calibrated version of the
Stroke-Thrombolytic Predictive Instrument using data from routinely treated stroke patients in the Safe Implementation
of Treatments in Stroke (SITS-UK) registry. Predictions in untreated patients were validated using data from the Virtual
International Stroke Trials Archive (VISTA). The probability of symptomatic intracerebral haemorrhage in treated patients
was incorporated using a scoring model from Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) data.
Results: The model predicts probabilities of haemorrhage, death, independence and dependence at 3-months,
with and without thrombolysis, as a function of 13 patient characteristics. Calibration (and inclusion of additional
predictors) of the Stroke-Thrombolytic Predictive Instrument (S-TPI) addressed issues of under and over prediction.
Validation with VISTA data confirmed that assumptions about treatment effect were just. The C-statistics for
independence and death in treated patients in the DAM were 0.793 and 0.771 respectively, and 0.776 for
independence in untreated patients from VISTA.
Conclusions: We have produced a DAM that provides an estimation of the likely benefits and risks of thrombolysis for
individual patients, which has subsequently been embedded in a computerised decision aid to support better
decision-making and informed consent.
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Background
The risks and benefits of thrombolysis for acute ischaemic
stroke vary from patient to patient depending on their
clinical characteristics. Even within licensing criteria, clini-
cians have expressed a desire for individualised predictions
[1]. Although predictive models for thrombolytic treat-
ment exist [2–4] the majority are derived from single or
pooled analyses of randomised controlled trials (RCTs)
[5–9]. Rothwell [10] has highlighted the issue facing doc-
tors of assessing external validity when taking evidence
from RCTs into account in determining whether their re-
sults can be reasonably applied to patients treated in rou-
tine practice. RCTs are infrequently powered to identify
all factors associated with the range of outcomes following
treatment. For example, the rate of symptomatic intrace-
rebral haemorrhage (SICH) is reported in trials, but the
low rates make identification of the factors associated with
this outcome difficult, yet the risk of haemorrhage is a fac-
tor in the decision to offer thrombolysis. Doctors have to
rely on information from observational studies where fac-
tors associated with SICH have been identified. Decision
analytic models (DAMs) are an established and explicit
way to synthesise available evidence about the outcomes
of healthcare interventions [11]. This paper describes the
development of a DAM that brings together results from
RCTs together with observational data to support decision
making about thrombolysis for individual patients. Devel-
oping a DAM of this type means identifying, combining
and validating the best sources of evidence and data about
the outcomes of interest in as methodologically a robust
way as possible. The DAM’s uses include the communica-
tion of likely risks, benefits and prognosis to patients/rela-
tives during the hyper-acute stroke period, supporting
informed consent, promoting patient/family involvement
in decision-making and modelling the implications of
stroke-related service developments.
In a previous paper we reported improved explanatory
power and relevance of a predictive model derived from
large scale RCTs of thrombolysis, the Stroke-Thrombolytic
Predictive Instrument (S-TPI) [12], with respect to out-
comes in individual patients seen in clinical practice, by
calibration with patient data from routine practice [13].
Calibration is the process whereby predicted outcomes
are compared to observed outcomes. In the S-TPI the
probability of a ‘good outcome’ is dependent on age,
systolic blood pressure (SBP), diabetes, sex, stroke severity
(National Institutes of Health Stroke Scale (NIHSS)), previ-
ous stroke, onset to treatment time and thrombolysis. Its
predictions are made in terms of the modified Rankin
score (mRS) [14]. The mRS measures the degree of disabil-
ity in carrying out daily activities on a six point scale and a
seventh point denoting death. Age, stroke severity and
serum glucose are predictors of a ‘catastrophic outcome’ an
mRS of 5 or 6. The S-TPI defined a ‘good outcome’ as a
mRS of ≤ 1 i.e.”able to carry out all usual activities, despite
some symptoms”. This definition is discordant with the def-
inition more typically used in clinical practice where mRS ≤
2 i.e. “able to look after own affairs without assistance, but
unable to carry out all previous activities” characterises a
‘good outcome’. The S-TPI does not include explicit pre-
dictions for SICH and related outcomes (subsequent in-
dependence, dependence and death), which are also
consequences of the decision to treat or not to treat al-
though the predictions are implicit in the S-TPI’s three-
month outcomes. We therefore aimed to develop a DAM
by re-calibrating the original S-TPI using data about pa-
tients treated in routine practice, as well as incorporating
risk of SICH and related outcomes.
Methods
Overview
The DAM was created using the predictions of the S-TPI
calibrated with SITS data. This enhanced model allows
prediction, for any set of inputs representing a patient, of
the probability of being in any one of the three states:
death (mRS = 6), dependence (2 ≤mRS < 6) and independ-
ence (mRS ≤ 2). Separately we calculated the risk of SICH
for that patient, if treated, and from what we know about
post-SICH outcomes we estimated the probability of:
SICH leading to death, dependence and independence.
These SICH outcomes were combined with the calibrated
S-TPI into the DAM.
Calibration of the predictive model of independence
(mRS ≤ 2) death and dependence
Calibration curves were constructed to establish the ac-
curacy of the S-TPI predictive equations for mRS ≤ 2 and
mRS = 6 in treated patients using data from SITS-UK [14]
and to confirm calibration was necessary. The SITS-UK
dataset contains information about patients who were
treated intravenous thrombolysis and includes outcome
data in the form of the mRS as well as the predictors used
in the DAM [12–14]. Calibration curves show whether
predictions from the S-TPI correspond with outcomes in
the SITS-UK population and how any under or over pre-
diction varies with outcome probabilities.
We applied the same data analysis strategy used to
calibrate the S-TPI in our previous report [12], adjust-
ing the S-TPI model because no association between
thrombolytic treatment and a catastrophic outcome (se-
vere disability or death, mRS 5 to 6) at three months exists
and SITS-UK patients might reasonably be expected to
have a different mortality risk than the patients in the
RCTs. Because death before three months is a competing
risk to a normal outcome, only cases surviving (mRS ≤ 5)
at three months were used in the calibration of S-TPI to
predict mRS ≤ 2. We also assumed that probability of
death associated with risk of SICH would be captured in
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the overall probability of death in treated patients. Further
analyses were undertaken to establish the improvement in
explanatory power of the model by including predictors of
independence (e.g. signs of current infarction on pre-treat-
ment brain scan, congestive heart failure, and blood glu-
cose) identified from the research literature [14] and our
previous work [13]. The record of signs of new current in-
farction were taken from Safe Implementation of Thromb-
olysis in Stroke-Monitoring Study (SITS-MOST), defined
as “Baseline CT examinations evaluated for early infarct
signs (hypodensity, dense artery sign)” [15] as recorded by
the responsible physician. SITS-MOST was an observa-
tional study that assessed the safety profile of Alteplase, the
drug used in thrombolysis [16].
The method of calibration consisted of logistic regres-
sions with the observed outcome (death or independence
from SITS-UK data) as the dependent variable. Along-
side the independent variables used in the construction
of the S-TPI an additional independent variable was in-
cluded. This additional variable was the predicted prob-
ability of the outcome of interest derived from the S-TPI.
In the case of ‘independence’ additional independent var-
iables were tested in the regression where evidence sug-
gested their potential in improving the explanatory
power of the model. As with the identification of inde-
pendent variables used in the S-TPI, a stepwise approach
was used to delete from the model, in turn, the independ-
ent variable whose removal most improved the model to
the point that removal of further variables no longer im-
prove the model. Consequently, any statistical signifi-
cance of remaining coefficients implies association with
under or over prediction. Coefficients associated with ei-
ther under or over prediction were applied to both the
treated and untreated predictions in order to maintain
the (net) treatment effect of thrombolysis (absolute dif-
ference in probability of independence [mRS ≤ 2] in
treated and untreated patients). If prediction discrepan-
cies were found to be associated with independent vari-
ables interacting with treatment effect we assumed that
the treatment effect reported by the S-TPI was correct,
and applied the calibration coefficients to both the
treated and untreated outcome predictions. To validate
our assumptions about predictions of outcomes in pa-
tients who do not receive thrombolytic treatment, we
compared outcomes in untreated patients (N = 4,360) re-
corded in Virtual International Stroke Trials Archive
(VISTA) [17] and compared the C-statistics, the general-
ised form of the area under the receiver operating curve
(AUC) [18], of the S-TPI to the calibrated S-TPI. VISTA
is a database containing anonymous data about individ-
ual patients from completed clinical trials of treatments
for stroke. C-statistics, represent the probability that the
prediction is better than chance. They range from 0.5 to
1.0, with 0.5 representing a model no better than chance
and 1.0 a model that perfectly predicts.0.7 is typically
considered reasonable and 0.8 strong [19].
A stepwise logistic regression analysis was performed
using SITS-UK (N = 2,401) data to establish statistically
significant predictors of death in the S-TPI at three
months in treated patients. We also investigated whether
the addition of blood glucose and the presence of an in-
farct on brain scan enhanced the prediction qualities of
the model for death. Dependence (mRS 3 to 5) at three
months was calculated as unity minus the sum of the
probabilities for independence and death.
To quantify the improvement in the predictive abilities
of the S-TPI, we tested its predictions for mRS ≤ 2 using
the SITS-UK dataset. Receiver operating curves (ROC)
were used to estimate the ability of the S-TPI at three
months to discriminate (i) between treated patients who
do and don’t benefit (mRS ≤ 2) from thrombolysis, and
(ii) between treated patients who die (mRS = 6) or sur-
vive (mRS ≤5). C-statistics were used to compare the
ability of the S-TPI to discriminate between patients that
would benefit or not from thrombolytic treatment.
Prediction of SICH and related outcomes
We used the SITS-MOST definition of SICH ‘NIHSS scores
worsening≥ 4 within 24 h and an intracerebral haemor-
rhage type PH2 (a space occupying hematoma of >30 % of
the infarct zone with substantial mass effect attributable to
the hematoma)’ [20]. Cases in the SITS-UK data that met
the criteria for the SITS-MOST definition of SICH were
too few (n = 18) to derive a prediction equation; therefore
the risk of SICH for treated patients was estimated used a
scoring model reported in the literature [21] derived from
the wider SITS-MOST population. A suitable predictive
equation for outcomes following SICH could not be iden-
tified. We used the following proportions that mapped
onto mRS ranges in our DAM: 6 % (mRS ≤ 2), 33 % (mRS
3 to 5) and 61 % (mRS 6) [20].
Data
Information about 4022 patients who were thrombolysed
between December 2002 and February 2010 were obtained
from SITS-UK. Cases with incomplete or unconfirmed
data for mRS at three months were excluded (n = 227). We
also applied range restrictions to predictors of mRS at
three months in the S-TPI (age ≥18, glucose ≤ 25 mmol;
systolic blood pressure ≤ 200 mm Hg; and onset time to
treatment ≤ 270 min), yielding sample sizes of 1,996 for
analysis of mRS 0 to 2 and 2,401 for analysis of death at
three months (Table 1). The table also describes the VISTA
untreated population used to validate outcomes in un-
treated patients. VISTA collates and provides access to
completed, anonymised RCT data for the purposes of
novel exploratory analyses. The data used to estimate the
risk of SICH was from patients in the international data set
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Table 1 Baseline characteristics of S-TPI cases and those in SITS-UK and VISTA with mRS of≤ 2 pre treatment
S-TPI
N = 2,131
SITS-UK, N = 2,401 VISTA untreated
N = 4,630
Characteristic Cases omitted from
analyses (n = 227)
Patients: surviving at
3-months (n = 1,996)
Patients: not surviving to
3-months (n = 405)
Age mean (SD) 65.9 (11.4) 67.8 (13.26) 66.7 (12.7) 73.3 (11.3) 70.5 (12.2)
Sex, % male 54.7 % 58.6 % 58.7 % 56.5 % 51.6 %
NIHSS score (median, IQR) 12 (8,17) 12 (7,18)b 12 (8,17) 19 (15,22) 13 (8,18)
Hypertension % 58.8 % 60.36 % 58.0 % 62.5 % 72.1 %a
Diabetes % 20.8 % 14.9 % 12.0 % 17.3 % 21.4 %
Prior stroke % 16.6 % 14.41 % 13.6 % 14.8 % 34.3 %a
Atrial fibrillation % 18.6 % 27.0 % 23.6 % 30.6 % 31.6 %
Onset time to treatment (OTT)
minutes (median, IQR)
235
(155,290)
146 (109,175) 150 (120, 175) 150 (120, 178) -
OTT, % within 3–4.5 h 61.3 % 15.3 % 16.6 % 17.3 % -
Systolic blood pressure, mm Hg
(mean, SD)
152.6
(20.3)
145.5 (21.8)a 146.9 (20.8) 147.9 (21.0) 156.8 (26.7)
Serum glucose mmol/l (median, IQR) 6.78
(5.83,8.58)
6.2 (5.6,7.8) 6.2 (5.4, 7.5) 6.9 (6.0, 8.4) 6.7 (5.8,8.5)
Signs of current infarction on
pre-treatment scan %
NA 23.9 % 24.3 % 34.8 % NA
Congestive heart failure % 12.1 % 4.5 % 4.6 % 6.9 % NA
aignoring missing values, bNational Institutes of Health Stroke Scale
S-TPI = Stroke-Thrombolytic Predictive Instrument
SITS-UK = Safe Implementation of Treatments in Stroke UK
Table 2 Results of calibration of S-TPI on mRS≤ 2 and on death
Parameter S-TPI (mRs ≤1) DAM correction factor (mRs≤ 2) S-TPI (mRs > 4) DAM correction factor (mRS > 5)
Intercept 1.0702 −0.1144 −7.580 −7.417a
Thrombolysis Treatment 3.3774
Age (per 1 year increase) 0.0173 −0.0259c 0.050 0.0418a
Systolic blood pressure, SBP (per 1 mmHg) −0.00488 0.00831c
Diabetes 0.7431
Male (vs. Female) 0.3757 0.1763d
NIHSSe (per 1 unit increase) −0.00764 −0.1372b 0.142 0.132a
Prior stroke 0.3728
Onset to treatment, OTT (per 1 min increase) 0.000333
Treatment* SBP −0.0117
Treatment* Male −0.4286
Treatment* Prior stroke −0.7738
Treatment* OTT -
Age* NIHSS −0.00285 0.00159c
Prediction of S-TPI NA 3.3896a NA 0
Presence of infarct on brain scan NA −0.4020a
Serum glucose (mmol/L, truncated at 25) - - 0.072 0.1024a
Signif. codes: >0.001a; 0.001b; 0.01c; 0.05d
eNational Institutes of Health Stroke Scale
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SITS-MOST; details of these patients are reported else-
where [21].
Results
The calibration curves showed that the S-TPI under-
and over-estimated the probability of mRS ≤ 2 and mRS
6 in SITS-UK patients respectively, confirming that cali-
bration was warranted. The C-Statistics were 0.785 for a
good outcome (mRS ≤ 2) and 0.770 for death.
The calibrated S-TPI Model for independence (mRS ≤ 2) in
treated patients
We found the original S-TPI accounted for 91 % of the
variability in ‘predicted’ probability of independence in
patients that survived for three months. Full details can
be found in Table 2. In the S-TPI, treatment interacts
with sex, onset time to treatment (OTT), systolic blood
pressure (SBP), stroke severity and previous stroke. Cali-
bration determined that sex, diabetes, prior stroke and
onset time to treatment were not statistically significant
predictors of discrepancies between the original S-TPI’s
predictions of independence and actual independence in
the SITS-UK population. Age, NIHSS score and systolic
blood pressure were statistically significant in the calibra-
tion of the S-TPI. The impact of increasing systolic blood
pressure on reducing the probability of a good outcome in
the S-TPI was lessened as was the effect of being male.
Age and stroke severity reduced the probability of a good
outcome more than predicted by the S-TPI. However for
stokes with an NIHSS score of 17 and over the probability
of a good outcome rose as age increased. In addition signs
of current infarction on pre-treatment imaging were asso-
ciated with improved prediction.
The calibrated S-TPI model for prediction of death
The S-TPI’s predictions for a catastrophic outcome (mRS
5 to 6) and the calibration for death (mRS 6) derived from
SITS-UK are given in Table 2. All parameters were statis-
tically significant predictors of death, which was consistent
with the S-TPI model for catastrophic outcomes, although
glucose in the DAM has a larger negative effect on prob-
ability of death than in the S-TPI.
Fig. 1 ROC curves for the calibrated S-TPI for treated (A&B) and untreated patients (C&D)
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Properties of the calibrated models for independence and
death, and validation of untreated outcomes using VISTA
data
The calibrated S-TPI models for independence (mRS ≤
2) showed an increase in the-C-statistic from 0.785 to
0.793 (Fig. 1a). The C-statistic when predicting death
was 0.771 in the calibrated S-TPI compared to 0.770 in
the original (Fig. 1b). The ROC curves for predictions
of independence in VISTA patients using the original
and calibrated S-TPI models are shown in Fig. 1c.
Compared with the original S-TPI model for independ-
ence in untreated patients, the calibrated S-TPI has im-
proved discrimination in predicting independence in
untreated patients from VISTA; it under- and over pre-
dicts at lower and higher probabilities of independence
respectively (Fig. 1d).
An overview of the DAM showing its inputs and their
relationships is show in Fig. 2.
Fig. 2 Decision Analytic Model, its inputs and predictions
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Predictions of the decision analytic model
In their paper describing the development of the S-TPI,
Kent and colleagues [11] presented the predicted out-
comes of a group of patients with and without thromb-
olysis. In Table 3 we report these outcomes alongside
the predictions from our calibrated version of the S-TPI.
Missing values were imputed using appropriate values
from the SITS-UK database. Reflecting the modified def-
inition of a good outcome (mRS ≤ 2instead of mRS ≤ 1),
the DAM predicts a greater likelihood of a good out-
come in untreated patients. With thrombolysis the prob-
abilities were in the main greater than these predicted by
the S-TPI. Predictions of a catastrophic outcome/ death
are lower in the DAM, as mRS = 5 is no longer included
in this category. The final column shows the probability
of SICH in treated patients regardless of final outcome
which is captured in the mRS ≤ 2 mRS > 5 values.
One-way sensitivity analyses
The DAM’s predictions across a range of values of one in-
put, whilst holding others constant, are shown in Fig. 3.
Other characteristics used in the predictions are a 70 year
old male, who is not diabetic, has not previously suffered a
stroke, systolic BP 140 mm/Hg, blood glucose 6.5 mmol/l,
and scored 14 on the NIHSS scale, was treated in 90 min
and had no infarction present on pre-treatment scan. In
each plot the broken lines show the probability of SICH
increases slightly with stroke severity and time to treat-
ment. The probability of death, shown by the solid lines,
also increases with stroke severity but is unaffected by
time to treatment. The grey areas represent the potential
gain in probability of independence.
Discussion
We have addressed the external validity issues of the S-TPI
by incorporating the outcomes of patients treated in rou-
tine clinical practice. By calibrating the S-TPI to accommo-
date the outcomes identified by clinicians as most relevant
to routine practice, adjusting its structure to isolate the ef-
fect of death, and incorporating predictors of additional
outcomes of interest, we have developed a tool that cap-
tures the variation in outcomes associated with individual
patient characteristics. We were able to validate our as-
sumptions about outcomes in untreated patients using a
second data set and concluded our assumptions were valid.
We have also addressed the feature of the S-TPI where
there are no explicit predictions of adverse effects of
thrombolysis as raised by Whitley et al. [22] and Emberson
et al. [23]. This is a result of the (valid at a population ra-
ther than the individual level) assumption that the net ef-
fect of thrombolysis on death is zero because any increases
in deaths in the acute phase of stroke caused by thromb-
olysis are offset by lives saved in the post-acute phase. Our
prediction of SICH quantifies the risks associated with
thrombolysis. As with any treatment decision, the key issue
is the balance between risks and benefits. The threshold of
SICH risk at which a physician might choose not to treat,
or a patient elects not to receive treatment, depends on the
potential benefits of treatment. The predictions allow phy-
sicians to weigh up the risks and benefits of treating any in-
dividual patient. For example, the 75 year old male patient
(in Table 3) treated at 165 min with a NIHSS of 19 has a
26 % chance of being independent without thrombolysis
and a 28 % chance when thrombolysed, yet has a 3.7 % of
SICH if treated. This prediction, in part, addresses the criti-
cisms of Whitley et al. [22] and Emberson et al. [23] that
predictions made by tools like the S-TPI and our DAM al-
ways predict benefit, they do identify patients where that
benefit is very small.
However, there are potential weaknesses of our ap-
proach. The SITS-UK data used to calibrate the S-TPI
was itself informed by the results of the original RCTs,
and patients less likely to have good outcomes following
thrombolysis are less likely to appear in SITS-UK. The
finding that the probability of a good outcome for stroke
patients with an NIHSS score of 17 and over rose as age
increased indicates potential selection bias. New research
into the risks of haemorrhage amongst untreated patients
would allow the DAM to reduce the potential over predic-
tion of risk of haemorrhage in treated patients. There is a
risk of over prediction of haemorrhage in treated patients
because we have not included the risk of haemorrhage in
untreated patients. This is likely to be small, and we
decided not to include the prediction of SICH in un-
treated patients because of the limited availability of data.
The third International Stroke Trial (IST3) [24] reported
6.5 times the number of SICH in treated patients com-
pared with patients not thrombolysed at seven days when
treatment was given within three hours.
The decision to offer any treatment involves consider-
ation of the probability and magnitude of benefits and the
risk and severity of any harms. Unlike the S-TPI, we in-
cluded explicit risks of SICH resulting from thrombolysis
alongside the estimates of likely benefit to highlight this
trade-off. The subsequent structured development process
by which the DAM was embedded into a computerised de-
cision aid for stroke thrombolysis (COMPASS), including a
mixed methods feasibility testing of a resultant gamma
prototype in clinical practice is described in a sister paper
(Flynn et al. [25]). Briefly, COMPASS was used in a prag-
matic fashion by 10 stroke clinicians in three acute stroke
units for patients eligible for thrombolysis. Findings dem-
onstrated usability and acceptability of COMPASS amongst
patients, relatives and clinicians to support clinicial decision
making or to obtain more detail on likely patient benefit
after a decision to offer thrombolysis. (in particular for pa-
tients at the extremes of the licensing criteria; for example
low NIHSS scores) and interpretation of risks and benefits
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Table 3 Individual patient predictions
Patient characteristics S-TPI DAM
Age Gender Diabetes Prior
Stroke
SBP
(mm Hg)
Glucose
(mmol/L)
NIHSS OTT mRS≤ 1 mRS≥ 5 mRS≤ 2 mRS > 5 SICH
No rtPA rtPA No rtPA rtPA
77 F Yes No 140 15.2 5 179 48 % 72 % 13 % 54 % 69 % 12 % 3.14 %
57 M Yes No 179 20.7 5 164 51 % 56 % 7 % 73 % 76 % 9 % 3.14 %
73 F No No 160 7.1 10 113 36 % 63 % 12 % 51 % 69 % 9 % 3.14 %
76 F Yes Yes 140 15.7 12 170 21 % 27 % 28 % 21 % 24 % 26 % 3.72 %
73 F No No 170 6.4 16 89 13 % 30 % 24 % 29 % 41 % 17 % 3.14 %
64 M No No 169 7.4 18 175 16 % 21 % 22 % 34 % 37 % 17 % 3.14 %
75 M No No 169 7.2 19 165 10 % 13 % 35 % 26 % 28 % 26 % 3.72 %
77 M No No 150 4.7 19 90 10 % 20 % 33 % 25 % 31 % 23 % 3.14 %
51 F No No 165 13.1 29 122 4 % 9 % 51 % 8 % 10 % 47 % 5.05 %
Imputing SITS-UK mean infarct = 0.294; Weight 80 kg; Aspirin Yes; Clopidogrel No; Hypertensive No
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Fig. 4 Prototype version of COMPASS
Fig. 3 Individual predictions of the S-TPI and DAM
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of thrombolysis, including overall net benefit for individual
patients were facilitated by the use of graphical risk presen-
tations, specifically pictographs showing outcomes with and
without thrombolysis at 3 months. The potential of COM-
PASS as a clinical training aid was also emphasised for cli-
nicians, as well as an adjunct to the telemedicine model of
stroke care was also emphasised by clinicians. The results
of this research are presented in a sister paper [25] and an
example of a prototype application embedding the DAM is
shown in Fig. 4.
Conclusion
A pragmatic approach to developing a model to provide
individualised outcome prediction for thrombolysis based
on individual patient characteristics has resulted in a model
that reflects the needs of clinicians. This was achieved by
incorporating feedback from clinicians about what out-
comes are important to support better decision making
with evidence about outcomes of patients treated in rou-
tine practice, alongside the best evidence on effectiveness
from RCTs. This predictive decision analytic model differs
from previous models as it combines evidence from a
range of sources, including trials and observational studies,
to support decision making. Building on the individualised
predictions of the S-TPI, our decision analytic model has
enhanced external validity and improved clinical applicabil-
ity to likely outcomes for individual patients.
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